241 related articles for article (PubMed ID: 35419668)
1. MR fingerprinting of the prostate.
Lo WC; Panda A; Jiang Y; Ahad J; Gulani V; Seiberlich N
MAGMA; 2022 Aug; 35(4):557-571. PubMed ID: 35419668
[TBL] [Abstract][Full Text] [Related]
2. Targeted Biopsy Validation of Peripheral Zone Prostate Cancer Characterization With Magnetic Resonance Fingerprinting and Diffusion Mapping.
Panda A; OʼConnor G; Lo WC; Jiang Y; Margevicius S; Schluchter M; Ponsky LE; Gulani V
Invest Radiol; 2019 Aug; 54(8):485-493. PubMed ID: 30985480
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance fingerprinting in prostate cancer before and after contrast enhancement.
Lee YS; Choi MH; Lee YJ; Han D; Kim DH
Br J Radiol; 2022 Mar; 95(1131):20210479. PubMed ID: 34415785
[TBL] [Abstract][Full Text] [Related]
4. Quantitative longitudinal mapping of radiation-treated prostate cancer using MR fingerprinting with radial acquisition and subspace reconstruction.
Yu VY; Otazo R; Wu C; Subashi E; Baumann M; Koken P; Doneva M; Mazurkewitz P; Shasha D; Zelefsky M; Cervino L; Cohen O
Magn Reson Imaging; 2023 Sep; 101():25-34. PubMed ID: 37015305
[TBL] [Abstract][Full Text] [Related]
5. Reproducibility of magnetic resonance fingerprinting-based T1 mapping of the healthy prostate at 1.5 and 3.0 T: A proof-of-concept study.
Sushentsev N; Kaggie JD; Slough RA; Carmo B; Barrett T
PLoS One; 2021; 16(1):e0245970. PubMed ID: 33513165
[TBL] [Abstract][Full Text] [Related]
6. The effect of gadolinium-based contrast agent administration on magnetic resonance fingerprinting-based T
Sushentsev N; Kaggie JD; Buonincontri G; Schulte RF; Graves MJ; Gnanapragasam VJ; Barrett T
Sci Rep; 2020 Nov; 10(1):20475. PubMed ID: 33235229
[TBL] [Abstract][Full Text] [Related]
7. Prostate Indeterminate Lesions on Magnetic Resonance Imaging-Biopsy Versus Surveillance: A Literature Review.
Gómez Rivas J; Giganti F; Álvarez-Maestro M; Freire MJ; Kasivisvanathan V; Martinez-Piñeiro L; Emberton M
Eur Urol Focus; 2019 Sep; 5(5):799-806. PubMed ID: 29525382
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of Novel Three-Dimensional Magnetic Resonance Fingerprinting of the Prostate Gland: Phantom and Clinical Studies.
Han D; Choi MH; Lee YJ; Kim DH
Korean J Radiol; 2021 Aug; 22(8):1332-1340. PubMed ID: 34047506
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
10. Development of a Combined MR Fingerprinting and Diffusion Examination for Prostate Cancer.
Yu AC; Badve C; Ponsky LE; Pahwa S; Dastmalchian S; Rogers M; Jiang Y; Margevicius S; Schluchter M; Tabayoyong W; Abouassaly R; McGivney D; Griswold MA; Gulani V
Radiology; 2017 Jun; 283(3):729-738. PubMed ID: 28187264
[TBL] [Abstract][Full Text] [Related]
11. Emerging MR methods for improved diagnosis of prostate cancer by multiparametric MRI.
Dwivedi DK; Jagannathan NR
MAGMA; 2022 Aug; 35(4):587-608. PubMed ID: 35867236
[TBL] [Abstract][Full Text] [Related]
12. T1 and T2 MR fingerprinting measurements of prostate cancer and prostatitis correlate with deep learning-derived estimates of epithelium, lumen, and stromal composition on corresponding whole mount histopathology.
Shiradkar R; Panda A; Leo P; Janowczyk A; Farre X; Janaki N; Li L; Pahwa S; Mahran A; Buzzy C; Fu P; Elliott R; MacLennan G; Ponsky L; Gulani V; Madabhushi A
Eur Radiol; 2021 Mar; 31(3):1336-1346. PubMed ID: 32876839
[TBL] [Abstract][Full Text] [Related]
13. Toward magnetic resonance fingerprinting for low-field MR-guided radiation therapy.
Mickevicius NJ; Kim JP; Zhao J; Morris ZS; Hurst NJ; Glide-Hurst CK
Med Phys; 2021 Nov; 48(11):6930-6940. PubMed ID: 34487357
[TBL] [Abstract][Full Text] [Related]
14. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Repeatability and Reproducibility of MR Fingerprinting in Phantoms and in Prostatic Tissue.
Lo WC; Bittencourt LK; Panda A; Jiang Y; Tokuda J; Seethamraju R; Tempany-Afdhal C; Obmann V; Wright K; Griswold M; Seiberlich N; Gulani V
Magn Reson Med; 2022 Oct; 88(4):1818-1827. PubMed ID: 35713379
[TBL] [Abstract][Full Text] [Related]
16. Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification.
Mendhiratta N; Rosenkrantz AB; Meng X; Wysock JS; Fenstermaker M; Huang R; Deng FM; Melamed J; Zhou M; Huang WC; Lepor H; Taneja SS
J Urol; 2015 Dec; 194(6):1601-6. PubMed ID: 26100327
[TBL] [Abstract][Full Text] [Related]
17. 3D MR fingerprinting (MRF) for simultaneous T1 and T2 quantification of the bone metastasis: Initial validation in prostate cancer patients.
Choi MH; Lee SW; Kim HG; Kim JY; Oh SW; Han D; Kim DH
Eur J Radiol; 2021 Nov; 144():109990. PubMed ID: 34638082
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric magnetic resonance imaging characteristics of normal, benign and malignant conditions in the prostate.
De Visschere PJ; Vral A; Perletti G; Pattyn E; Praet M; Magri V; Villeirs GM
Eur Radiol; 2017 May; 27(5):2095-2109. PubMed ID: 27491874
[TBL] [Abstract][Full Text] [Related]
19. Prostate Cancer Detection Percentages of Repeat Biopsy in Patients with Positive Multiparametric Magnetic Resonance Imaging (Prostate Imaging Reporting and Data System/Likert 3-5) and Negative Initial Biopsy. A Mini Systematic Review.
Grivas N; Lardas M; Espinós EL; Lam TB; Rouviere O; Mottet N; van den Bergh RCN;
Eur Urol; 2022 Nov; 82(5):452-457. PubMed ID: 35985901
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer lesion detection, volume quantification and high-grade cancer differentiation using cancer risk maps derived from multiparametric MRI with histopathology as the reference standard.
Gibbons M; Simko JP; Carroll PR; Noworolski SM
Magn Reson Imaging; 2023 Jun; 99():48-57. PubMed ID: 36641104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
